Scarica l'app Stockscreener
13.75
2.27%
-0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$14.07
Aprire:
$14.38
Volume 24 ore:
8.72M
Relative Volume:
1.81
Capitalizzazione di mercato:
$10.67B
Reddito:
$220.00K
Utile/perdita netta:
$-1.21B
Rapporto P/E:
-8.5729
EPS:
-1.6039
Flusso di cassa netto:
$-387.48M
1 W Prestazione:
+5.12%
1M Prestazione:
-14.17%
6M Prestazione:
-19.31%
1 anno Prestazione:
-31.80%
Intervallo 1D:
$13.56
$14.60
Intervallo di 1 settimana:
$12.92
$14.60
Portata 52W:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.75 | 10.67B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Avoiding Lag: Real-Time Signals in (SMMT) Movement - Stock Traders Daily
Why is SMMT stock tumbling today? - MSN
Summit rebounds after nearly $50M insider purchase - MSN
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc (SMMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Summit Therapeutics Inc (SMMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Summit Therapeutics Inc (SMMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why Summit Therapeutics Is Staying In The Biotechnology Spotlight? - Kalkine Media
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Investor Outlook: Evaluating A Potential 103.85% Upside - DirectorsTalk Interviews
Summit Therapeutics Raises $500 Million in Public Offering to Support Lung Cancer PipelineGAAP Earnings Report - newsline.com
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum - timothysykes.com
Summit Therapeutics stockholders approve directors and incentive plan - The Globe and Mail
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering - Insider Monkey
Insider Buying: Summit Therapeutics Co-CEO, President & Director Bought US$1.5m Of Shares - simplywall.st
Summit Therapeutics files for $500M common stock offering; shares slide over 9% - MSN
Summit Therapeutics (SMMT) Surges 7% as Bulls Test Key ResistanceRelative Volume - newsline.com
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M St - GuruFocus
5 Best Buy-the-Dip Stocks to Invest In Now - Insider Monkey
SMMT Jumps As Ivonescimab Trial Success Fuels Financing Drive - StocksToTrade
Summit Therapeutics (NASDAQ: SMMT) investors approve directors and 8M-share incentive plan boost - Stock Titan
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares By Investing.com - Investing.com Australia
Summit Therapeutics(SMMT.US) 10% Shareholder Buys US$49.99 Million in Common Stock - Moomoo
Insider Stock Purchases: June 12, 2026 - Quiver Quantitative
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares - Investing.com
Co-CEO Mahkam Zanganeh (SMMT) reports spouse’s 3.81M-share open-market buy - Stock Titan
Summit Therapeutics (SMMT) Shares Rebound After Co-CEO's $50M Stock Purchase - GuruFocus
Summit Therapeutics (SMMT) Gains 2.83% as Stock Approaches Key Resistance LevelLow Beta Factor - newsline.com
Summit gains after nearly $50M insider buy (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics stock rises after CEO share purchase By Investing.com - Investing.com Canada
Summit Therapeutics stock rises after CEO share purchase - Investing.com
Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing - Moomoo
Summit Therapeutics co-CEO Robert Duggan buys $49.9m in stock - Investing.com India
Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares - StreetInsider
Summit Therapeutics Co-Chief Executive Officer Purchased Shares Worth Over $49M - TradingView
Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market - Stock Titan
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results - Yahoo Finance
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):